ASLAN Pharmaceuticals cordially invites you to their hybrid R&D Day in person at the St. Regis Hotel in New York City and virtually via webcast.

The event will include presentations from management as well as Key Opinion Leaders (KOLs) Peter A. Lio, MD (Northwestern University Feinberg School of Medicine) and Shawn Kwatra, MD (Johns Hopkins University).

ASLAN’s leadership team will discuss their pipeline portfolio led by eblasakimab, a novel, first-in-class monoclonal antibody that targets the IL-13 receptor α1 subunit (IL-13Rα1) for the treatment of atopic dermatitis (AD). New clinical data from eblasakimab’s Phase 1b proof-of-concept study and translational data on the unique mechanism of action will be shared, with an update of latest clinical efforts in AD. Additional details will follow closer to the event.

A live question and answer session will follow the formal presentations.